About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 82 record(s)
Req # A-2020-000034
Adverse Reaction Report (AER). Report number: E2B_02876672.Organization: Health Canada
June 2020
Req # A-2020-000051
Adverse Reaction Report (AER) for ENTYVIO. Report numbers: E2B_02968814, E2B_02935743, E2B_02935720, E2B_02980774, E2B_02928576, E2B_02931979, E2B_02928948, E2B_02971530, E2B_02982966, E2B_02935644, E2B_02955576, E2B_02987178.Organization: Health Canada
June 2020
Req # A-2020-000052
Adverse Reaction Report (AER) for VEDOLIZUMAB. Report numbers: E2B_02959635, E2B_02972254, E2B_02931989, E2B_02965282, E2B_02983115, E2B_02973212, E2B_02940189, E2B_02975948, E2B_02928892.Organization: Health Canada
June 2020
Req # A-2020-000087
Adverse Reaction Report (AER). Report number: 000730668.Organization: Health Canada
June 2020
Req # A-2020-000190
Adverse Reaction Report (AER) for Teriflunomide. Report number: E2B_02548709.Organization: Health Canada
June 2020
Req # A-2020-000093
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02732621, E2B_02732642, E2B_02743629, E2B_02755293, E2B_02743830, E2B_02760135, E2B_02745999, E2B_02689032, E2B_02748963, E2B_02749663, E2B_02694913, E2B_02755340, 728891, E2B_02755380, 728902.Organization: Health Canada
June 2020
Req # A-2020-000098
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02938064, E2B_02938254, E2B_02902613, E2B_02902662, E2B_02902504, E2B_02902540, E2B_02902753, E2B_02902509, E2B_02903041, E2B_02901919, E2B_02947663, E2B_02949936, E2B_02870856, E2B_02884210, E2B_02879951, E2B_02318078, E2B_02884120, E2B_02884190, E2B_02875456, E2B_02884166.Organization: Health Canada
June 2020
Req # A-2020-000112
Adverse Reaction Report (AER) for Cipralex® (escitalopram). Report number: E2B_02961876.Organization: Health Canada
June 2020
Req # A-2020-000127
Adverse Reaction Report (AER). Report numbers: E2B_02868934, E2B_02871948, E2B_02874537, E2B_02875447.Organization: Health Canada
June 2020
Req # A-2020-000133
Adverse Reaction Report (AER). Report number: 000735507.Organization: Health Canada
June 2020